Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced that Dr. Inbar Maymon-Pomeranchik will participate at MjBizCon in Las Vegas from October 20-22, 2021. Dr. Maymon-Pomeranchik will engage in a Regulatory Panel Session and will hold one-on-one meetings to discuss the drug candidate RCC-33 for colorectal cancer treatment. Interested parties can reach out via email. Cannabics has recently expanded its IP portfolio and advisory board, including renowned experts in oncology.
Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced that CEO Eyal Barad will present at the Edison Open Forum: Cannabinoids 2021 on October 19, 2021. The presentation will address the development of synthetic cannabinoid-based drugs for colorectal cancer and FDA regulatory review challenges. Barad expressed pride in representing the company, highlighting industry trends and opportunities. The public can access the forum by registering at this link.
Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced on Oct. 18, 2021, the filing of two new Provisional Patent applications focused on cancer treatment, particularly colorectal cancer. This adds to the company's IP portfolio, which now consists of 8 patent families, including 5 granted patents and 19 pending applications. Executive Chairman Gabriel Yariv emphasized the importance of these patents for addressing unmet needs in colorectal cancer therapy. The company is known for developing cannabinoid-based medicines for cancer treatment.
Cannabics Pharmaceuticals Inc. (CNBX) announced participation in Benzinga's Cannabis Capital Conference in NYC on October 14-15, 2021. CEO Eyal Barad and Dr. David Sans will represent the company, highlighting its focus on developing cancer-related cannabinoid-based medicines. Cannabics is licensed in Israel to conduct scientific and clinical research on cannabinoid formulations. Interested parties can contact CEO Eyal Barad via email. For more updates about Cannabics, visit their website or follow them on social media.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has announced a refreshed corporate image, including a new logo and website, as of September 30, 2021. This update aligns with the company’s strategic shift from pre-clinical to clinical stage development, focusing on FDA compliance. The new website, www.cannabics.com, features details on drug candidates and corporate news vital for investors. The update also includes a new corporate presentation showcasing Cannabics' ongoing developments in cannabinoid-based medicine.
Cannabics Pharmaceuticals (OTCQB: CNBX) announced its participation in the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston on September 22, 2021. This event focuses on cannabinoid-based treatments for medical conditions and involves discussions on clinical trials globally. Company President Gabriel Yariv expressed pride in attending this leading conference, highlighting its significance in the cannabinoid research community. Cannabics is recognized as a global leader in developing cancer-related cannabinoid-based medicine, with ongoing R&D based in Israel.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced the appointment of Dr. Ilya Reznik as Head of Psychedelic Inspired Medicine. This strategic move aims to develop new therapies targeting mental health conditions. Dr. Reznik, a renowned neuropsychiatrist, brings extensive expertise in psychedelic research. His appointment follows the launch of the company’s Psilocybin and Psilocin Research Program in Israel. CEO Eyal Barad expressed confidence in Dr. Reznik's ability to advance the company's initiatives in psychedelic medicine, which may benefit patients with unmet needs.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has appointed Dr. Sigal Tavor, a Hemato-Oncology expert, to its Board of Advisors. This move is part of the company's strategy to enhance its Drug Discovery Platform and expand its focus on Hematology alongside its existing cancer programs. The company has also recently broadened its Board with several notable experts in the field, including Prof. Caroline Robert. The additions are aimed at advancing the company’s clinical projects and drug development initiatives.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced the appointment of Prof. Caroline Robert, a leading expert in Melanoma, to its Board of Advisors on August 4, 2021. This strategic move aligns with the company’s efforts to develop a new treatment for Melanoma using its unique cannabinoid-based technology. Prof. Robert brings extensive experience in clinical and translational research, having authored over 325 articles on the topic. Her involvement is expected to enhance Cannabics' research capabilities in the field of cancer therapies.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced the appointment of Dr. Gil Feiler as an Independent Director to its Board, having previously served as a Permanent Observer since October 2019. Dr. Feiler, a prominent economist, also leads the company's Advisory Board. His extensive experience includes senior roles in both academia and business sectors, with a focus on Middle East economics. This appointment follows the recent nomination of Dr. Inbar Maymon-Pomeranchik as another Independent Director, signaling a strengthening of the company's governance.